Business Wire

Aker BP Leverages Cognite Atlas AI™ to Pioneer an AI-First Future in Exploration and Production

16.9.2025 16:00:00 EEST | Business Wire | Press release

Share

Aker BP, one of Europe's largest independent oil companies, and Cognite, the global leader in industrial AI, deepen their strategic partnership through the expanded adoption of Cognite Atlas AI™,harnessing the power of AI agents to improve efficiency, reduce costs, and elevate productivity. This enhanced collaboration puts Aker BP at the forefront of leveraging agentic AI to drive significant value and transform its operations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250903134233/en/

Aker BP Leverages Cognite Atlas AI™ to Pioneer an AI-First Future in Exploration and Production

Aker BP's "AI-first strategy" was developed to help lead the energy sector into a data-driven future by seamlessly integrating AI applications within industrial settings and business objectives to innovate and deliver results across the business. This includes automating complex processes and allowing engineers to easily access industrial expertise.

"Our collaboration with Cognite on Atlas AI represents a significant leap forward in our digital transformation journey," said Paula Doyle, Chief Digital Officer, Aker BP. "This partnership underscores our commitment to a continued AI-first, data-driven approach with Cognite, embracing agentic AI to further drive efficiency, enhance decision-making, and optimize our operations across the board."

Cognite Atlas AI offers pre-built agents and a low-code workbench for building industrial AI agents, accelerating the journey towards autonomous operations. Integrated with the robust data foundation provided by Cognite Data Fusion®, the collaboration supports Aker BP's span of various strategic areas where AI is being leveraged to drive significant operational advancements and value.

This AI-first partnership includes streamlining critical workflows by automating document processing for enhanced supply chain efficiency and proactive barrier management. This includes initiatives like automatic equipment registration, which has the potential to reduce a significant number of engineering hours for Aker BP. Building an AI-ready data foundation for predictive maintenance and using AI to optimize production chemistry and overall performance is also underway.

The most recent collaboration includes creating AI agents for root cause analysis (RCA). These agents identify relevant information, create cause maps, and suggest RCA steps. These agents reduce engineers' time to perform this analysis by over 70%.

"We tested other AI solutions, but they fell short," said Tor Arne Amdal, Senior Reliability Engineer at AkerBP. "What we needed was contextualized intelligence. In our industrial work, it's not enough to just have data; you need the right data, in the right context, at the right time. This combination provides the precise, reliable answers that help us make faster decisions. After testing various solutions, we chose Cognite because it could meet our specific needs for AI-supported RCA workflows."

"Aker BP's legacy isn't just about being a digital leader; it's about pioneering the future," said Francois Laborie, EVP, Strategic Projects, Cognite. "This partnership is a powerful testament to their unwavering commitment to an AI-first strategy. By merging Aker BP's deep industry expertise with Cognite's Atlas AI, we're doing more than just solving today's challenges—we're equipping them with the internal competence to scale AI across their entire business, fundamentally empowering their workforce for tomorrow."

Witness firsthand how agentic AI is transforming industrial operations and hear directly from Aker BP and other industry leaders at Cognite's Industrial AI and Data Conference Impact 2025.

About Aker BP
Aker BP is a company engaged in exploration, field development, and production of oil and gas on the Norwegian continental shelf. The company operates the field centres Valhall, Ula, Edvard Grieg/Ivar Aasen, Alvheim, and Skarv, and is a partner in the Johan Sverdrup field. Measured in production, Aker BP is one of the largest independent oil companies in Europe.

About Cognite
Cognite makes GenAI work for industry. Leading energy, manufacturing, and power & renewables enterprises choose Cognite to deliver secure, trustworthy, and real-time data to transform their asset-heavy operations to be safer, more sustainable, and profitable. Cognite provides a user-friendly, secure, and scalable platform that makes it easy for all decision-makers, from the field to remote operations centers, to access and understand complex industrial data, collaborate in real-time, and build a better tomorrow. Visit us at www.cognite.com, and follow us on LinkedIn and X.

About Cognite Atlas AI™
Cognite Atlas AI™ unlocks the full potential of industrial data, empowering teams to make faster, more confident decisions and accelerate operational efficiency and innovation at scale. Cognite Atlas AI includes a growing library of preconfigured agents, a low-code agent builder, purpose-built industrial tools, and a curated selection of LLMs with benchmarking. It also utilizes the real-time OT, IT, and engineering data in Cognite Data Fusion®, ensuring that agents deliver accurate, traceable, and trustworthy results for industrial workflows.

To learn more about enabling agents for industry, please see the "Cognite Atlas AI" Definitive Guide to Industrial Agents and visit https://www.cognite.com/en/product/atlas.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250903134233/en/

Contacts

Media Contact:
Michelle Holford, VP of Global PR
michelle.holford@cognite.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye